A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder

被引:0
|
作者
Sanjay J Mathew
Ralitza Gueorguieva
Cynthia Brandt
Maurizio Fava
Gerard Sanacora
机构
[1] Mental Health Care Line,Menninger Department of Psychiatry & Behavioral Sciences
[2] Michael E. DeBakey VA Medical Center,Department of Psychiatry
[3] Baylor College of Medicine,Department of Biostatistics
[4] Yale University School of Medicine,Departments of Emergency Medicine and Anesthesiology
[5] Yale School of Public Health,Department of Psychiatry
[6] Yale University School of Medicine,undefined
[7] Massachusetts General Hospital,undefined
来源
Neuropsychopharmacology | 2017年 / 42卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to antidepressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site, 8-week, randomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison design comprised of two phases of 4 weeks. Patients with MDD in a current major depressive episode (N=104) with an inadequate response to either a prospective or a historical trial of an antidepressant medication were randomized in a 2 : 3 : 3 ratio to the treatment sequences of riluzole/riluzole, placebo/placebo, and placebo/riluzole, respectively. The primary outcome was change in depression severity, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary efficacy outcomes included the response rate, defined as at least a 50% improvement in MADRS, Clinical Global Impressions severity and improvement subscales, and patient-reported measures of depression and cognitive function. Eighty-five patients completed the randomized treatment phases. Treatment groups did not differ in mean change in MADRS scores, response rate, or in any secondary efficacy outcomes. Riluzole was generally well tolerated, with a side effect profile consistent with its clinical use. In conclusion, a fixed dose of riluzole (100 mg/day) did not show adjunctive antidepressant efficacy compared to placebo. The trial was adequately powered to detect a moderate riluzole effect, and the risk for exaggerated placebo responses was mitigated. The lack of efficacy suggests that mechanisms underlying riluzole’s neuroprotective effects are insufficient for clinical response in treatment-resistant depression.
引用
收藏
页码:2567 / 2574
页数:7
相关论文
共 50 条
  • [41] Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, multicenter, double-blind, placebo-controlled trial
    Emslie, Graham J.
    Dineen Wagner, Karen
    Kutcher, Stan
    Krulewicz, Stan
    Fong, Regan
    Carpenter, David J.
    Lipschitz, Alan
    Machin, Andrea
    Wilkinson, Christel
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (06): : 709 - 719
  • [42] Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Rickels, Karl
    Athanasiou, Maria
    Robinson, Donald S.
    Gibertini, Michael
    Whalen, Heidi
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (03) : 326 - 333
  • [43] Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Zajecka, John
    Schatzberg, Alan
    Stahl, Stephen
    Shah, Amy
    Caputo, Angelika
    Post, Anke
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (02) : 135 - 144
  • [44] An 8-week, Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Ziprasidone in Patients with Major Depressive Disorder Receiving Treatment with Escitalopram
    Papakostas, George
    Swee, Michaela B.
    Baer, Lee
    Shelton, Richard C.
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S344 - S345
  • [45] Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial
    Talaei, Ali
    Moghadam, Maryam Hassanpour
    Tabassi, Sayyed Abolghasem Sajadi
    Mohajeri, Seyed Ahmad
    JOURNAL OF AFFECTIVE DISORDERS, 2015, 174 : 51 - 56
  • [46] Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial
    Jeon, Hong Jin
    Fava, Maurizio
    Mischoulon, David
    Baer, Lee
    Clain, Alisabet
    Doorley, James
    DiPierro, Moneika
    Cardoos, Amber
    Papakostas, George I.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 332 - 338
  • [47] Levetiracetam as an Adjunctive Treatment for Mania: A Double-Blind, Randomized, Placebo-Controlled Trial
    Keshavarzi, Amir
    Sharifi, Aziz
    Jahangard, Leila
    Soltanian, Alireza
    Bruehl, Annette Beatrix
    Ahmadpanah, Mohammad
    Brand, Serge
    NEUROPSYCHOBIOLOGY, 2022, 81 (03) : 192 - 203
  • [48] Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial
    Hirschmann, S
    Dannon, PN
    Iancu, I
    Dolberg, OT
    Zohar, J
    Grunhaus, L
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (05) : 556 - 559
  • [49] Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: A double-blind, randomized, placebo-controlled trial
    French, Jacqueline
    Brandt, Christian
    Friedman, Daniel
    Biton, Victor
    Knapp, Lloyd
    Pitman, Verne
    Chew, Marci
    Dubrava, Sarah
    Posner, Holly B.
    EPILEPSIA, 2014, 55 (08) : 1220 - 1228
  • [50] Topiramate augmentation in patients with resistant major depressive disorder: A double-blind placebo-controlled clinical trial
    Mowla, Arash
    Kardeh, Ehsan
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (04): : 970 - 973